EUSA Pharma (EUSA) has obtained global commercialisation rights of oncology product Isqette (dinutuximab beta) from Apeiron Biologics.

Isqette is a monoclonal antibody developed to specifically target the GD2 antigen expressed on the surface of neuroblastoma cells and subsequently trigger a selective immunological attack against these tumour cells.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Under the agreement, Apeiron will be paid with an upfront fee from EUSA, a portion of which will be conditioned to EU approval.

Additionally, EUSA will make regulatory milestone payments in other important territories and royalties on future product sales.

"As a rapidly growing specialist pharma company we have made great progress since our launch 18 months ago, and we plan to continue this through further product acquisition and in-licensing."

EUSA Pharma CEO Lee Morley said: "We are delighted to acquire the global rights to Isqette, which is a perfect fit with our strategic focus in the specialist oncology field and will allow us to leverage our commercial infrastructure in the EU and expand our presence in the US.

See Also:

"Dinutuximab beta is already used extensively across Europe, where it is included in a number of treatment protocols, and we look forward to bringing this life-saving therapy to patients around the world.  

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“As a rapidly growing specialist pharma company we have made great progress since our launch 18 months ago, and we plan to continue this through further product acquisition and in-licensing."

EUSA is planning to submit a regulatory filing for Isqette in the US next year, and after being approved will market the product directly through its established US infrastructure.

The company is also planning to introduce the product in other territories such as Japan.